Citations 1
Pharmacogenomic Study—A Pilot Study of the Effect of Pharmacogenomic Phenotypes on the Adequate Dosing of Verapamil for Migraine Prevention
Chen, Yi‐Chieh , Mandrekar, Jayawant N. , Robertson, Carrie E. , Starling, Amaal J. , Cutrer, F. Michael , Robertson, Carrie E , Chen, Yi-Chieh , Wang, Han , Chiang, Chia‐Chun
No container title available | December 15, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available
Abstract OBJECTIVE Using individual pharmacogenomic phenotypes to investigate the factors affecting the efficacy and tolerability of verapamil for migraine prevention. BACKGROUND Verapamil has a wide range of dosing in headache disorders without reliable tools to predict the optimal doses for an individual. METHODS This is a retrospective chart review examining adults with existing pharmacogenomic reports at Mayo Clinic who had used verapamil for migraine. Effects of six cytochrome P450 phenotypes on the minimum effective and maximum tolerable verapamil doses for migraine prevention were assessed. RESULTS The mean minimum effective and maximum tolerable doses for the 33 patients in final analysis were 178.2(20–320) mg and 227.9(20–480) mg. A variety of CYP2C9, CYP2D6, and CYP3A5 phenotypes were found, without significant association with the verapamil doses after adjusting for age, sex, body mass index, and smoking status. CONCLUSIONS We demonstrated a wide range of effective and tolerable verapamil doses used for migraine in a cohort with various pharmacogenomic phenotypes.